

Cheleste M Thorpe

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5495134/publications.pdf>

Version: 2024-02-01

17
papers

372
citations

1039406

9
h-index

1058022

14
g-index

18
all docs

18
docs citations

18
times ranked

537
citing authors

#	ARTICLE	IF	CITATIONS
1	Shiga Toxin-Producing <i>Escherichia coli</i> Infection. <i>Clinical Infectious Diseases</i> , 2004, 38, 1298-1303.	2.9	150
2	Enhanced preservation of the human intestinal microbiota by ridinilazole, a novel <i>Clostridium difficile</i> -targeting antibacterial, compared to vancomycin. <i>PLoS ONE</i> , 2018, 13, e0199810.	1.1	44
3	Effect of <i>Lactobacillus rhamnosus</i> GG Administration on Vancomycin-Resistant <i>Enterococcus</i> Colonization in Adults with Comorbidities. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 4593-4599.	1.4	41
4	Ridinilazole, a narrow spectrum antibiotic for treatment of <i>Clostridioides difficile</i> infection, enhances preservation of microbiota-dependent bile acids. <i>American Journal of Physiology - Renal Physiology</i> , 2020, 319, G227-G237.	1.6	29
5	Effects of Shiga Toxin Type 2 on a Bioengineered Three-Dimensional Model of Human Renal Tissue. <i>Infection and Immunity</i> , 2015, 83, 28-38.	1.0	23
6	Activation of the Classical Mitogen-Activated Protein Kinases Is Part of the Shiga Toxin-Induced Ribotoxic Stress Response and May Contribute to Shiga Toxin-Induced Inflammation. <i>Infection and Immunity</i> , 2016, 84, 138-148.	1.0	20
7	Update on <i>Clostridium difficile</i> . <i>Current Treatment Options in Gastroenterology</i> , 2006, 9, 265-271.	0.3	17
8	Antimicrobial susceptibility and ribotypes of <i>Clostridium difficile</i> isolates from a Phase 2 clinical trial of ridinilazole (SMT19969) and vancomycin. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 2078-2084.	1.3	15
9	A Novel <i>Zak</i> Knockout Mouse with a Defective Ribotoxic Stress Response. <i>Toxins</i> , 2016, 8, 259.	1.5	10
10	A repeat offender: Recurrent extraintestinal <i>Clostridium difficile</i> infection following fecal microbiota transplantation. <i>Anaerobe</i> , 2018, 51, 68-72.	1.0	7
11	Shiga toxin-producing <i>Escherichia coli</i> infection in South India. <i>Journal of Medical Microbiology</i> , 2009, 58, 1525-1526.	0.7	5
12	<i>Citrobacter rodentium</i> (iStx2dact), a murine infection model for enterohemorrhagic <i>Escherichia coli</i> . <i>Current Opinion in Microbiology</i> , 2022, 65, 183-190.	2.3	5
13	Epidemiologic Trends in <i>Clostridium difficile</i> Isolate Ribotypes in United States from 2010 to 2014. <i>Open Forum Infectious Diseases</i> , 2017, 4, S391-S391.	0.4	4
14	Preface. <i>Infectious Disease Clinics of North America</i> , 2013, 27, xiii-xiv.	1.9	2
15	1681 Randomized Clinical Trial of the Recovery of Probiotics <i>Lactobacillus rhamnosus</i> GG (LGG) and <i>Bifidobacterium animalis</i> subspecies <i>lactis</i> (BB-12) from the Gastrointestinal (GI) Tract of Healthy Volunteers. <i>Open Forum Infectious Diseases</i> , 2014, 1, S449-S449.	0.4	0
16	Impact of Body Mass Index (BMI) on the Effect of a <i>Lactobacillus Rhamnosus</i> GG (LGG)/ <i>Bifidobacterium Animalis</i> Subspecies <i>Lactis</i> BB-12 (BB-12) Combination on Gut Microbiota (P20-023-19). <i>Current Developments in Nutrition</i> , 2019, 3, nzz040.P20-023-19.	0.1	0
17	The role of Shiga toxin in promoting transepithelial migration of neutrophils. <i>FASEB Journal</i> , 2013, 27, 131.9.	0.2	0